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Magnetic resonanceAbstract Aim of the work: The aim of this study was to examine osteopontin (OPN) levels in both
plasma and synovial ﬂuid of patients with primary knee osteoarthritis (OA) and to investigate their
relationship with severity of the disease.
Patients and methods: Fifty patients with primary knee OA were compared to twenty-ﬁve appar-
ently healthy controls. OPN levels in plasma and synovial ﬂuid were measured using enzyme-linked
immunosorbent assay. Severity of knee pain was assessed by the Western Ontario and McMaster
Universities osteoarthritis index. Radiographic grading of knee OA was performed by Kellgren–
Lawrence criteria. Magnetic resonance imaging (MRI) was also performed on painful knees.
Results: Plasma OPN was higher in patients (159.65 ± 28.56 ng/ml) than controls
(90.45 ± 23.63 ng/ml). OPN in plasma and synovial ﬂuid was correlated with severity of knee pain
(r= 0.878, r= 0.795, P< 0.001). Cartilage loss, marginal osteophytes and subchondral bone cyst
were the commonest MRI ﬁndings in knee OA. MRI detected also patients with early knee OA that
were not detected by plain radiography.
Conclusion: OPN serves as a biochemical marker of disease severity in knee OA. It also could be
predictive to the progression of disease.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Osteoarthritis (OA) is the most widespread joint affecting
disease characterized by articular cartilage degeneration,
subchondral bone sclerosis, osteophyte formation, and
synovial inﬂammation [1].OA is the most common arthritis of the elderly and may
lead to severe symptoms like pain, malformation of the
joint and disability [2]. All joints may be affected, but the
knee is the most clinically signiﬁcant site of primary OA
involvement [3].
Although OA is generally assessed using standard radio-
graphic images in clinical practice, biochemical markers can
be used to detect the disease and determine its severity.
Osteopontin (OPN) is an extracellular matrix glycopro-
tein that is a potential inﬂammatory cytokine [4]. As the
name implies, OPN may have a role in bone metabolism.
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and bone resorption is blocked by inhibition of this interac-
tion [5]. OPN may also contribute directly to the regulation
of mineral crystal formation and growth. It binds hydroxy-
apatite and suppresses crystal formation both in vitro and
in vivo [6,7]. OPN is also a regulator of inﬂammation. It
regulates macrophage differentiation and recruitment [8]. It
also functions as a chemotactic factor and co-stimulator of
T cells [9].
Plasma OPN concentrations were signiﬁcantly higher in
systemic lupus erythematosus (SLE) patients with renal
impairment and in SLE patients than controls. Increase in
OPN correlated signiﬁcantly with SLE disease activity index
in all patients. OPN production could be associated with the
inﬂammatory process of SLE development and may serve as
a potential disease marker of SLE [10]. Plasma OPN was ele-
vated fourfold in patients with systemic sclerosis (n= 70,
89.1 ± 52.4 ng/ml) compared with healthy controls (n= 21,
23.8 ± 3.7 ng/ml) and 1.4-fold compared with patients with
idiopathic pulmonary hypertension (n= 59, 63.4 ± 44.2 ng/
ml). The possibility of using OPN inhibitors as a novel
therapeutic target of T-cell chemotaxis could be, because of
monoclonal OPN antibodies used with great success in
collagen-induced arthritis. Furthermore, OPN measurement
would be an attractive tool for early detection of pulmonary
ﬁbrosis [11].
The polymorphisms of the OPN gene 443C/T and the
66/T were signiﬁcantly associated with the OA risk and
radiographic severity in 750 patients with primary knee OA
[12]. Dong et al. [13] found that serum OPN and thrombin
cleaved OPN to OPN ratio of synovial ﬂuid were correlated
with OA severity.
The standard diagnostic investigation is the plain
radiograph for knee OA which lacks sensitivity [14]. Magnetic
resonance imaging (MRI) detected more cases of knee OA
than radiograph as concluded by Schiphof et al. [15]. MRI
could detect early structural changes of knee OA besides signs
of disease progression.
The aim of the present work was to investigate osteopontin
levels in both plasma and synovial ﬂuid of patients with
primary knee osteoarthritis and study their relationship with
severity of the disease.2. Patients and methods
Fifty primary knee osteoarthritis female patients were included
in the study at the Physical Medicine, Rheumatology and
Rehabilitation Department, Ain Shams University Hospitals.
The diagnosis of patients met the American College of Rheu-
matology Criteria for diagnosis of knee OA [16]. Twenty-ﬁve
apparently healthy females were also enrolled as controls in
this study.
The local ethical committee approved this study and an
informed consent was obtained from subjects sharing in the
study.
2.1. Clinical evaluation
Patients were subjected to full medical history taking and thor-
ough clinical examination with stress on age, weight, height
and body mass index (BMI). Knee pain was graded from 0to 4 (0 = none, 1 = slight, 2 = moderate, 3 = very and
4 = extremely) on the basis of visual analogue scale. This
was calculated for ﬁve different activities (on walking, stair
climbing, nocturnal, rest and weight bearing) quoted from
the Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) [17].2.2. Radiological assessment
1-Plain radiographs, anteroposterior weight bearing standing
position for both knees, were taken. The radiographic grading
of OA was performed by using the Kellgren–Lawrence criteria
(K–L) [18,19].2.3. 2-Magnetic resonance imaging (MRI)
MRI was performed with a 1.5 Tesla scanner (Philips Medical
Systems, Japan). Images from pulse sequence were used in the
assessment of knee OA features: axial, sagittal and coronal fat
saturated, proton density weighted dual spin echo images.
Evaluation of tibiofemoral joint (tibial plateau, central weight
bearing and posterior portions of femoral condyles) was
according to the presence or absence of certain features in
painful knees. These features include cartilage loss, marginal
osteophytes, meniscal lesion, subchondral bone cyst, subchon-
dral bone sclerosis, bone marrow edema, synovial effusion,
ligamentous abnormalities, Baker’s cyst and bone attrition.
For statistical purpose, absence of each speciﬁc feature was
graded zero and its presence was graded one.2.4. Osteopontin measurement
Osteopontin (OPN) levels in plasma for patients and controls
and in synovial ﬂuid for patients only were measured by
enzyme-linked immunosorbent assay (ELISA) (Quantkine
ELISA kit D 05T00 USA). Plasma samples were collected
using EDTA as anticoagulant. The results were expressed in
ng/ml relative to standards included in test kit.
Statistical analysis: The collected data were organized and
statistically analyzed using SPSS version 18. Range, mean,
standard deviation and Student’s t test for comparison
between two means were calculated for quantitative data.
ANOVA test used to compare between more than two groups.
Pearson’s correlation co-efﬁcient (r) tested the association
between two variables.3. Results
Fifty patients with primary knee OA complained of knee pain
and were compared to 25 apparently healthy controls. All
patients and controls were female. Their age ranged from
48–78 years with mean ± SD (60.60 ± 9.38) for patients, 48–
74 years (59.93 ± 8.49) for the control group. Pain grading
ranged from 2 to 16 with mean ± SD (9.28 ± 2.64). There
was no signiﬁcant difference between patients and controls in
age and BMI (Table 1). Both groups of patients and controls
were obese as the mean BMI was 29.62 ± 2.01 and
30.39 ± 1.74 (respectively).
Figure 1 Anteroposterior radiograph with K-L grade 3 in Rt.
Knee in a patient with knee osteoarthritis.
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was higher in synovial ﬂuid 222.23 ± 41.42 ng/ml. In controls,
plasma OPN was 90.45 ± 23.63 ng/ml. OPN in synovial ﬂuid
was higher with respect to paired plasma. There was a signiﬁ-
cant difference between patients and controls as regards the
plasma OPN levels (t= 8.534, P< 0.001) as shown in
Table 1.
Radiographic data revealed different percentages for K–L
scores in knee OA. About 10% of patients were grade G1,
56% G2, 27% G3 (Fig. 1) and 7% G4.
As regards MRI ﬁndings, the tibiofemoral compartment
was more frequently and more severely involved in OA of knee
joint than the patellofemoral compartment and medial
tibiofemoral joint was most commonly involved. The most
common ﬁndings were cartilage damage, marginal osteo-
phytes, subchondral bone cyst and bone marrow edema.
Cartilage loss of medial tibiofemoral compartment was in
about 80% of patients and about 5% had damage of lateral
tibiofemoral cartilage. Marginal osteophytes were present in
about 74% of patients and subchondral cyst was found in
about 52% (Fig. 2A). Bone marrow edema was in about
44% of patients. Subchondral sclerosis was in 32%, synovial
effusion in 24% while mensical abnormalities were in about
12% (Fig. 2B) and Baker’s cyst was in 16% (Fig. 2C).
Ligamentous abnormalities were in about 4% of patients.
Plasma and synovial ﬂuid OPN levels were signiﬁcantly
different with severity of K–L score for knee OA (F= 19.05
for plasma and F= 24.47 for synovial OPN, p< 0.001). Fur-
thermore, OPN levels were signiﬁcantly different with some
MRI features as cartilage loss (t= 9.46 for plasma, t= 5.22
for synovial, p< 0.001), subchondral cyst (t= 23.96,
p< 0.001, t= 6.89, p< 0.002), marginal osteophytes
(t= 12.80, t= 7.58, P< 0.001) and for synovial effusion
(t= 9.51, t= 16.62, p< 0.001). On the other hand, no statis-
tical signiﬁcant difference in OPN was found for the presence
of subchondral sclerosis or meniscal or ligamentous
abnormalities.
OPN level in plasma signiﬁcantly correlated with synovial
OPN (r= 0.806, P< 0.001) (Fig. 3). Also, OPN level in both
plasma and synovial ﬂuid was signiﬁcantly correlated with
severity of knee pain (r= 0.878, r= 0.795, p< 0.001) (Figs. 4
and 5). No signiﬁcant correlation was found between plasma
or synovial OPN and either age or BMI of the patients
(r= 0.119 and r= 0.029 for plasma, r= 0.091 and
r= 0.185 for synovial OPN, p> 0.05).Table 1 Comparison between knee OA patients and controls as r
plasma and synovial ﬂuid (SF).
Range Knee OA patients C
(Mean ± SD)
Age (years) 48–78 4
(60.64 ± 9.38) (5
BMI (kg/m2) 26.8–34.1 2
(29.62 ± 2.01) (3
Plasma OPN 93.6–200.3 4
(ng/ml) (159.65 ± 28.56) (9
SF OPN 120–290 –
(ng/ml) (222.23±41.42)
* Signiﬁcantly different.4. Discussion
Osteopontin has been implicated in biological activities,
including regulation of mineral crystal formation and growth
[6,7]. It also has a regulator role in inﬂammation as a
chemotactic factor and costimulator of T cells [8].
It has been shown that OPN was identiﬁed in synovial ﬂuid
[20] of patients with rheumatoid arthritis (RA) and in plasma
and synovial ﬂuid with knee OA [4]. However, the relationship
between OPN levels and disease severity has rarely been specif-
ically determined in patients with knee OA.
OPN was highly detected by immunohistochemistry pre-
dominantly in RA synovial lining cells. ELISA also showed
a marked increase of OPN levels in synovial ﬂuid of patients
with RA and with OA compared to the control plasma OPN
levels. The enhanced local production of OPN in rheumatoid
joints may be involved in the pathogenesis of RA [21]. In
addition, the levels of OPN correlated signiﬁcantly with
interleukin-17 and the frequency of T-helper 17 (Th17) cells
in the synovial ﬂuid of RA patients that revealed a critical role
of OPN in Th17 differentiation in rheumatoid synovitis [22].
This study showed a marked increase of OPN levels in both
plasma and synovial ﬂuid of patients with knee OA compared
to control levels. Our ﬁndings suggest enhanced local andegards age, body mass index (BMI) and osteopontin (OPN) in
ontrols t p-value
8–74 0.261 0.795
9.93 ± 8.49)
7.3–33 1.327 0.189
0.39 ± 1.74)
9.2–140.3 8.534 <0.001*
0.45 ± 23.63)
Figure 2 MRI of the left knee in a patient with knee osteoarthritis. (A) T1W coronal section shows marginal osteophytes (black plus)
and subchondral cyst (white arrow), (B) White arrow in sagittal weighted dual spin shows degenerated oblique tear of the posterior horn
of the medial meniscus, (C) Mild synovial effusion and small Baker’s cyst.
Figure 3 Correlation between plasma and synovial osteopontin
(OPN) level in patients with knee osteoarthritis.
Figure 4 Correlation between plasma osteopontin (OPN) and
severity of knee pain in patients with knee osteoarthritis.
32 H.M. Haider et al.systemic production of OPN in primary knee OA. The possible
mechanism that could explain why OPN levels in synovial ﬂuid
were elevated is the release of OPN in extracellular matrix or
by increased production. This theory copes with the
identiﬁcation of OPN as an extracellular glycoprotein and as
a potential inﬂammatory cytokine [4]. The elevated values of
plasma OPN in OA patients could reﬂect its release from
injured joints.
As OPN levels in plasma and synovial ﬂuid were signiﬁ-
cantly correlated with severity of knee pain and radiologic
progression of the disease either by Kellegren–Lawrence score
or MRI ﬁndings, measurements of plasma and/or synovial
levels of OPN could possibly serve as a biochemical parameter
for determining disease severity. It might be also a predictive ofprognosis with respect to the progression of the osteoarthritic
disease process. Additional studies may provide further infor-
mation regarding the value of OPN as a potential marker to
monitor the course of OA.
These ﬁndings are supported by Honsawek et al. [23] and
Mohammed et al. [24] studies who had suggested that OPN
in plasma and synovial ﬂuid was related to progressive joint
damage in knee OA using the Kellgren–Lawrence criteria.
Another study [25] found higher OPN levels in synovial ﬂuid
and articular cartilage in ﬁfty patients compared to ten healthy
controls. It was associated with progressive joint damage by
using K–L criteria and concluded that OPN was likely to be
a useful biomarker for determining disease severity and pro-
gression in knee OA. In contrast to the previous studies, our
Figure 5 Correlation between synovial ﬂuid osteopontin (OPN)
and severity of knee pain in patients with knee osteoarthritis.
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severity and MRI ﬁndings to assess disease severity.
In this study, some patients complained of knee pain and
had multiple abnormalities of MRI despite lack of radio-
graphic OA (5 patients, 10% were K–L = 1) which indicates
an early stage of Knee OA. It reﬂects the higher sensitivity
of MRI for early detection of knee OA. It seems that majority
of MRI ﬁndings in tibiofemoral compartment of knee joint
and K–L scores were well correlated. This ﬁnding is supported
by Joshi et al. study [26] who found that increasing K–L scores
were associated with more frequent and more severe defects of
cartilage, bone marrow edema, osteophytes, subchondral cysts
and sclerosis in tibiofemoral compartments besides joint effu-
sion and presence of meniscal tears. They concluded that those
ﬁndings reinforce the evolving concept that knee OA is a whole
organ disease and MRI imaging is capable of showing the
bone and soft tissue evidence of knee OA at an early stage.
Further study by Schiphof et al. [15] recorded that deﬁnition
of tibiofemoral OA by MRI is more sensitive in detecting
structural knee OA.
It is noticed from our study that older age group had more
abnormalities of all types of MRI lesions. Otherwise, cartilage
loss and marginal osteophytes were the commonest MRI ﬁnd-
ings and subchondral bone cyst and bone marrow edema were
common in about half of patients. In an interesting study,
Guermazi et al. [27] stated that changes which were indicative
of OA were commonly present in the knees of most people
aged ﬁfty and above who have no radiographic evidence of
tibiofemoral OA. Osteophytes, cartilage damage and bone
marrow edema were common in either painful or painless
knees that represented an early stage OA. Another study [28]
found that bone marrow lesions (BMLs) detected by MRI
were highly prevalent in elderly Asian population (N= 358).
BMLs were signiﬁcantly correlated with knee pain severity.
On the same point, Hunter et al. [29] found that BMLs were
unlikely to resolve and often got larger overtime. Enlarging
BMLs were strongly associated with more cartilage loss. Some
studies detected a role of OPN in knee OA following rupture
of cruciate ligaments. Yamaga et al. [30] found after a month
of anterior cruciate ligament rupture both OPN full length and
N-terminal fragment (N-half) levels in SF of patients werepositively correlated with severity of joint pain. They suggested
that OPN full and N-half had distinct functions in articular
cartilage homeostasis and in human joint pain. Another study
in vitro, thrombin-cleaved OPN levels in SF were elevated four
weeks after posterior cruciate ligament transection in rabbit
model. The OPN peaking was at 24 weeks after surgery
(p< 0.00001). They concluded that thrombin cleaved OPN
in SF provided a useful marker of OA disease severity and
progression [31].
It should be pointed out that a limitation of this study is the
effect of joint sites other than the knee need to be taken into
account. However, this limitation decreased as patients mainly
complained of knee pain. Furthermore, the female predomi-
nance of patients with OA may lead to a potential bias in
comparing the levels of OPN because controlled data obtained
from a large sample size are currently not available.
In summary, patients with primary knee OA have elevated
levels of plasma OPN compared to healthy controls. We
performed this study with the goal of relating plasma and
synovial ﬂuid OPN levels to the progression of knee OA.
Plasma OPN was signiﬁcantly correlated with synovial OPN
and both were correlated to severity of knee pain and magni-
tude of OA radiographic and MRI progression.
In conclusion osteopontin measurement may serve as a
biochemical marker of disease severity of primary knee OA
in female Egyptian patients. It also could be predictive to the
progression of knee OA. Further longitudinal investigations
are warranted to elucidate the inﬂuence of OPN on disease
outcome.Conﬂict of interest
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